Researchers have found that the investigational drug selumetinib shuts down the signaling of genetic mutations that prevent some patients’ thyroid cancer tumors from absorbing radioiodine, the most effective treatment for the disease.
Dr. Huang discusses how minimally invasive, video-assisted, and robotic surgical techniques improve the treatment of patients with lung, esophageal, and thyroid cancers.
In 2003, Mary McCabe was recruited to lead Memorial Sloan-Kettering Cancer Center’s Cancer Survivorship Initiative and since that time has worked to develop a comprehensive program for cancer survivors, which includes follow-up care, research, and education and training.
At Memorial Sloan-Kettering, as the genetics revolution continues to flourish, discoveries made in the laboratory are increasingly producing real-world benefits for cancer patients.
